Physician profile
Brooke Adele Chezem
NPI 1245980903
$2,319.04
in general payments reported to CMS, 2019-2025
25 companies · $748 in 2025
The $748 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $618 · 2024: $809 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $349.92 | 2023-2025 | Farxiga, Lokelma, Andexxa |
| E.R. Squibb & Sons, L.L.C. | $275.23 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $240.15 | 2023-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.28 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $147.88 | 2023-2025 | Ozempic, Rybelsus |
| Atricure, INC. | $125.82 | 2023 | |
| Boston Scientific Corporation | $123.42 | 2025 | Watchman Access System |
| Amgen INC. | $120.98 | 2023-2025 | Repatha, Repatha |
| Pfizer INC. | $118.40 | 2022-2024 | |
| Kestra Medical Technology Services, INC. | $106.39 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $82.67 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $69.28 | 2024-2025 | |
| Scpharmaceuticals INC. | $49.86 | 2023-2024 | |
| Cvrx, INC. | $49.24 | 2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.30 | 2024-2025 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $41.04 | 2024 | Hillrom - Eli280 Cardiograph |
| Lexicon Pharmaceuticals, INC. | $35.48 | 2023 | Inpefa |
| Genzyme Corporation | $33.78 | 2024 | |
| Vital Connect, INC | $27.22 | 2024 | Vitalpatch Rtm |
| Alnylam Pharmaceuticals INC. | $16.85 | 2023 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $15.56 | 2024 | Arcalyst |
| Philips North America LLC | $15.31 | 2022 | |
| Irhythm Technologies, INC. | $14.63 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $13.98 | 2022 | |
| Esperion Therapeutics, INC. | $13.37 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Chezem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.